Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.regg.2025.101650 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Ketamine treatment of dementia-associated behavioral disorders. Case report].
Rev Esp Geriatr Gerontol
March 2025
Departamento de Bioquímica y Biología Molecular, Universidad de Sevilla, Sevilla, España.
Special issue on "Ketamine, MDMA, and psychedelics in the treatment of neuropsychiatric disorders".
Asian J Psychiatr
March 2025
Institute of Brain Science and Brain-inspired Research, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China.
Telemedicine Prescribing by US Mental Health Care Providers: National Cross-Sectional Survey.
JMIR Form Res
March 2025
Doxy.me, Inc, Charleston, SC, United States.
Background: In the postpandemic era, telemedicine continues to enable mental health care access for many people, especially persons living in areas with mental health care provider shortages. However, as lawmakers consider long-term telemedicine policy decisions, some question the safety and appropriateness of prescribing via telemedicine, and whether there should be requirements for in-person evaluation, especially for controlled substances.
Objective: Our objective was to assess US telemental health care provider perceptions of comfort and perceived safety in prescribing medications, including controlled substances, via telemedicine.
Assessment of complement cascade components in patients with major depressive disorder.
Brain Behav Immun
March 2025
Pathophysiology of Neuropsychiatric Disorders Program, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; Research and Development, Charlie Norwood VA Medical Center, Augusta, GA, USA. Electronic address:
Recent evidence suggests that the rapid-acting antidepressant ketamine has immune regulatory functions. The complement system is an important component of the innate immune response and plays a key role in synaptic plasticity. An increase in complement component 3 (C3) expression was previously found in the prefrontal cortex of individuals with depression.
View Article and Find Full Text PDFCurrent evidence for the role of rapid-acting antidepressants (RAAD) in bipolar depression? A perspective and plan for action.
Biol Psychiatry
March 2025
Goethe University Frankfurt, University Hospital, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.
After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap in research on bipolar depression. While several antipsychotics have been investigated for their efficacy in bipolar depression due to the reduced risk of mania induction, research on RAADs, such as (es)ketamine, remains scarce despite their demonstrated safety and effectiveness.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!